Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Reed Friend, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani

Research output: Contribution to journalReview article

  • 5 Citations

Abstract

Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

LanguageEnglish (US)
Pages893-900
Number of pages8
JournalDrug Design, Development and Therapy
Volume11
DOIs
StatePublished - Mar 20 2017

Fingerprint

Multiple Myeloma
Antibodies
Plasma Cells
Immunoglobulin G
Monoclonal Antibodies
elotuzumab
Signaling Lymphocytic Activation Molecule Family

Keywords

  • CS1
  • Elotuzumab
  • Multiple myeloma
  • Refractory
  • Relapsed
  • SLAMF7
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma. / Friend, Reed; Bhutani, Manisha; Voorhees, Peter M.; Usmani, Saad Z.

In: Drug Design, Development and Therapy, Vol. 11, 20.03.2017, p. 893-900.

Research output: Contribution to journalReview article

@article{99e01f93f6ca4a0b8505f67ccfa0756b,
title = "Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma",
abstract = "Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.",
keywords = "CS1, Elotuzumab, Multiple myeloma, Refractory, Relapsed, SLAMF7, Treatment",
author = "Reed Friend and Manisha Bhutani and Voorhees, {Peter M.} and Usmani, {Saad Z.}",
year = "2017",
month = "3",
day = "20",
doi = "10.2147/DDDT.S98053",
language = "English (US)",
volume = "11",
pages = "893--900",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

AU - Friend, Reed

AU - Bhutani, Manisha

AU - Voorhees, Peter M.

AU - Usmani, Saad Z.

PY - 2017/3/20

Y1 - 2017/3/20

N2 - Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

AB - Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

KW - CS1

KW - Elotuzumab

KW - Multiple myeloma

KW - Refractory

KW - Relapsed

KW - SLAMF7

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85016130803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016130803&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S98053

DO - 10.2147/DDDT.S98053

M3 - Review article

VL - 11

SP - 893

EP - 900

JO - Drug Design, Development and Therapy

T2 - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -